Summary of the Mycoplasma genitalium genetic susceptibility, to macrolide and fluoroquinolone antimicrobials, from specimens received by the PHE reference service in 2018 and from rectal specimens (and a swab from an unknown site) sourced from patients coinfected with Chlamydia trachomatis
| 23S rRNA | M. genitalium-positive reference specimens received in 2018 (n=488) | C. trachomatis/M. genitalium-positive specimens (n=23) | ||||
| No. | % | 95% CI | No. | % | 95% CI | |
| Susceptible | 153 | 31.4 | 27.6 to 35.6 | 4 | 17.4 | 7.0 to 37.1 |
| Resistant | 290 | 59.3 | 55.0 to 63.7 | 14 | 60.9 | 40.8 to 77.8 |
| A2058G | 151 | 52.1 | 46.3 to 57.8 | 6 | 42.9 | 21.4 to 67.4 |
| A2058T | 5 | 1.7 | 0.7 to 3.8 | 1 | 7.1 | 1.3 to 31.5 |
| A2059C | 6 | 2.1 | 1.0 to 4.4 | 0 | – | – |
| A2059G | 128 | 44.1 | 38.5 to 49.9 | 7 | 50.0 | 26.8 to 73.2 |
| Did not amplify | 45 | 9.2 | 7.0 to 12.1 | 5 | 21.7 | 9.7 to 41.9 |
| parC | No. | % | 95% CI | No. | % | 95% CI |
| Susceptible | 394 | 80.7 | 77.0 to 84.0 | 18 | 78.3 | 58.1 to 90.3 |
| Resistant | 34 | 7.0 | 5.0 to 9.6 | 1 | 4.4 | 0.8 to 21.0 |
| S83I | 17 | 50.0 | 34.1 to 65.9 | |||
| S83R | 2 | 5.9 | 1.6 to 19.1 | 1 | 100 | – |
| D87N | 13 | 38.2 | 23.9 to 55.0 | |||
| D87Y | 2 | 5.9 | 1.6 to 19.1 | |||
| Unknown* | 7 | 1.4 | 0.7 to 2.9 | 1 | 4.4 | 0.8 to 21.0 |
| G81C | 1 | 14.3 | 2.6 to 51.3 | |||
| S83N | 4 | 57.1 | 25.0 to 84.2 | |||
| S84P | 2 | 28.6 | 8.2 to 64.1 | |||
| D87V | 0 | – | – | 1 | 100 | – |
| Did not amplify | 53 | 10.9 | 8.4 to 13.9 | 3 | 13.0 | 4.5 to 32.1 |
*Mutations detected have unknown clinical significance.
PHE, Public Health England.